

Antoris® MR

Trimetazidine Dihydrochloride

Description

Trimetazidine (**Antoris® MR**), the first of a new class of metabolic agents, known as 3-KAT inhibitors, which optimizes cardiac metabolism under ischemic conditions. Trimetazidine (**Antoris® MR**) displays anti-ischemic effects without inducing hemodynamic changes and improves the status of the ischemic myocardium. Trimetazidine (**Antoris® MR**) exerts its antianginal effects through a direct cytoprotective action on the myocardium, thereby avoiding the side-effects of impaired left ventricular function, excessive peripheral vasodilatation and other disadvantages associated with other antianginal agents.

Mode of action

Trimetazidine (**Antoris® MR**) has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Trimetazidine (**Antoris® MR**) reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β -oxidation. This is made possible by a selective inhibition of an enzyme of fatty acid β -oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in: reduction in fatty acid oxidation; stimulation of glucose oxidation. Thus, the coupling of glycolysis with glucose oxidation is improved and ATP production is further increased, while cell acidosis and Ca^{2+} overload are limited.

Composition

Antoris® MR Tablet: Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg

Indications

Trimetazidine (**Antoris® MR**) is indicated for long term ischemic heart disease. Trimetazidine (**Antoris® MR**) delays the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.

Dosage & administration

The usual dosage is one tablet at meal times in the morning and evening.

Contraindications

Trimetazidine Dihydrochloride is contraindicated to patients who have known hypersensitivity to this drug.

Side effects

Trimetazidine is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

Use in pregnancy and lactation

It is preferable not to take during pregnancy. There is no information on the secretion of trimetazidine into breast milk. However, breast feeding should be discontinued if the use of trimetazidine is considered essential.

Precautions

Trimetazidine is not a curative treatment for angina attacks or an initial treatment for unstable angina.

Drug interactions

No drug interaction so far has been reported.

Storage

Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.

Packaging

Antoris® MR Tablet: Each carton containing 21X2 tablets in Alu-Alu blister strip.

087201



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.